Real World Testing of a Brain-Computer Interface to Operate a Commercial Augmentative and Alternative Communication System
The University of Pittsburgh's clinical trial focuses on the innovative application of BCI technology to enhance communication for individuals with severe disabilities, such as ALS, TBI, and cerebral palsy. The market for AAC devices is expanding, driven by increasing awareness and demand for assistive technologies. This study's findings could position the University of Pittsburgh as a leader in the AAC-BCI space, potentially attracting partnerships or funding from healthcare providers and technology developers. Competitive implications include the need to monitor existing AAC solutions and emerging BCI technologies that may enter the market. Diligence considerations should include assessing the scalability of the technology and its integration into existing healthcare frameworks.
Indication: Amyotrophic Lateral Sclerosis
Modality: medical device
Target: Brain-Computer Interface (BCI) technology for Augmentative and Alternative Communication (AAC) systems.
Sponsor: University of Pittsburgh
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Brain-Computer Interface (BCI) technology for Augmentative and Alternative Communication (AAC) systems.
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis, Brain Stem Stroke, Cerebral Palsy, Traumatic Brain Injury, Speech Disorders
Condition normalized: Amyotrophic Lateral Sclerosis, Brain Stem Stroke, Cerebral Palsy, Traumatic Brain Injury, Speech Disorders
Modality raw: medical device
Modality normalized: medical device
Target raw: Brain-Computer Interface (BCI) technology for Augmentative and Alternative Communication (AAC) systems.
Target normalized: Brain-Computer Interface (BCI) technology for Augmentative and Alternative Communication (AAC) systems.